Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Clinical Study Evaluating the Preliminary Efficacy of Human Allogeneic Induced Pluripotent Stem Cell (iPSC)-Derived Motor Neuron Progenitor Cells (XS228 Cell Injection) in Patients With Subacute Spinal Cord Injury

NCT06974968 is registered in ClinicalTrials.gov with XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd. as lead sponsor.

NCT NCT06974968
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06974968 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Clinical Study Evaluating the Preliminary Efficacy of Human Allogeneic Induced Pluripotent Stem Cell (iPSC)-Derived Motor Neuron Progenitor Cells (XS228 Cell Injection) in Patients With Subacute Spinal Cord Injury
Lead sponsor
XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd.
Phase
Phase 2
Overall status
Not yet recruiting
Start date
May 25, 2028
Completion date
May 26, 2031
Enrollment
60 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

clinical trial, efficacy, human motor neuron progenitor, induced pluripotent stem cells, rct, safety, spinal cord injury, transplantation